

James W Murrough

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/615471/james-w-murrough-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

10,138
citations

49
h-index

100
g-index

162
ext. papers

12,633
ext. citations

7.3
avg, IF

6.36
L-index

#	Paper	IF	Citations
137	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City.. <i>International Archives of Occupational and Environmental Health</i> , 2022 , 1	3.2	4
136	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.. <i>Translational Psychiatry</i> , 2022 , 12, 12	8.6	1
135	The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.. <i>CNS Drugs</i> , 2022 , 36, 2076-7		1
134	Beyond the neuron: Role of non-neuronal cells in stress disorders.. <i>Neuron</i> , 2022 ,	13.9	2
133	Pharmacological Treatments for Anhedonia.. <i>Current Topics in Behavioral Neurosciences</i> , 2022 , 1	3.4	
132	Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder.. <i>Translational Psychiatry</i> , 2022 , 12, 209	8.6	0
131	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. <i>Molecular Psychiatry</i> , 2021 , 26, 5140-5149	15.1	23
130	Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. <i>Translational Psychiatry</i> , 2021 , 11, 565	8.6	3
129	Intrasubject functional connectivity related to self-generated thoughts. <i>Brain and Behavior</i> , 2021 , 11, e01860	3.4	1
128	Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic: A Symptomics Analysis. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	4
127	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021 , 178, 383-399	11.9	67
126	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021 , 178, 437-446	11.9	6
125	Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	4
124	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Focus (American Psychiatric Publishing)</i> , 2021 , 19, 222-242	1.1	2
123	Moral distress in frontline healthcare workers in the initial epicenter of the COVID-19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning. <i>Depression and Anxiety</i> , 2021 , 38, 1007-1017	8.4	20
122	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. <i>Neuropsychopharmacology</i> , 2021 , 46, 2266-2277	8.7	3
121	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 383-391	5.8	7

120	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 151-157	4.4	0
119	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2021 , 35, 124-127	4.6	1
118	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2021 , 178, 193-202	11.9	37
117	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. <i>Depression and Anxiety</i> , 2021 , 38, 1108-1119	8.4	2
116	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. <i>Journal of Medical Internet Research</i> , 2021 , 23, e31295	7.6	3
115	Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City. <i>Chronic Stress</i> , 2021 , 5, 2470547020977891	3	27
114	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles.. <i>Frontiers in Nutrition</i> , 2021 , 8, 780226	6.2	0
113	Dissociating self-generated volition from externally-generated motivation. <i>PLoS ONE</i> , 2020 , 15, e0232949	4.7	2
112	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020 , 45, 1656-1663	8.7	23
111	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	36
110	A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020 , 26, 760-768	50.5	63
109	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. <i>Advances in Pharmacology</i> , 2020 , 89, 163-194	5.7	3
108	Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo ultra-high field 7-Tesla MRI study. <i>NeuroImage: Clinical</i> , 2020 , 25, 102148	5.3	6
107	Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. <i>Neuropsychopharmacology</i> , 2020 , 45, 975-981	8.7	36
106	Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	25
105	Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. <i>JAMA Psychiatry</i> , 2020 , 77, 172-179	14.5	50
104	Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 696-710	3.8	20
103	Neural correlates of rumination in major depressive disorder: A brain network analysis. <i>NeuroImage: Clinical</i> , 2020 , 25, 102142	5.3	30

102	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 29-45	2.6	59
101	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 783-790	5.8	7
100	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , 2020 , 266, 615-620	6.6	12
99	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , 2020 , 11, 595584	5	37
98	The role of the locus coeruleus in the generation of pathological anxiety. <i>Brain and Neuroscience Advances</i> , 2020 , 4, 2398212820930321	4	24
97	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020 , 25, 1592-1603	15.1	125
96	Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based case-control study. <i>Psychological Medicine</i> , 2020 , 50, 29-37	6.9	12
95	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2020 , 25, 1323-1333	15.1	26
94	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , 2019 , 3, 2470547019877880	3	0
93	The Neurobiology of Resilience: Complexity and Hope. <i>Biological Psychiatry</i> , 2019 , 86, 406-409	7.9	10
92	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , 2019 , 44, 1233-1238	8.7	20
91	Neurobiology of Resilience: Interface Between Mind and Body. <i>Biological Psychiatry</i> , 2019 , 86, 410-420	7.9	85
90	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2019 , 44, 1812-1819	8.7	21
89	Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1827-1845	15.1	79
88	Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. <i>Journal of Psychiatric Research</i> , 2019 , 111, 186-192	5.2	10
87	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. <i>Neuropsychopharmacology</i> , 2019 , 44, 390-398	8.7	11
86	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. <i>Patient</i> , 2019 , 12, 527-537	3.7	6
85	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1140, 585-600	3.6	2

84	Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. <i>Translational Psychiatry</i> , 2019 , 9, 94	8.6	24
83	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2019 , 17, 232-237	1.1	0
82	ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. <i>Contemporary Clinical Trials</i> , 2019 , 77, 19-26	2.3	16
81	Determinants and Predictive Value of Clinician Assessment of Short-Term Suicide Risk. <i>Suicide and Life-Threatening Behavior</i> , 2019 , 49, 614-626	3.9	21
80	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , 2018 , 230, 56-64	6.6	28
79	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018 , 175, 150-158	11.9	311
78	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018 , 11, 75-84	5.1	14
77	Acetyl-L-carnitine deficiency in patients with major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 8627-8632	11.5	68
76	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 3-11	5.8	38
75	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2018 , 18, 82-84	64.1	33
74	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018 , 8, 280	8.6	18
73	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018 , 1,	15.7	5
72	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. <i>Lancet, The</i> , 2017 , 389, 834-845	40	269
71	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , 2017 , 218, 277-283	6.6	30
70	Neuropeptide Y, resilience, and PTSD therapeutics. <i>Neuroscience Letters</i> , 2017 , 649, 164-169	3.3	41
69	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. <i>Translational Psychiatry</i> , 2017 , 7, e1065	8.6	102
68	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 472-486	64.1	234
67	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. <i>Human Brain Mapping</i> , 2017 , 38, 6068-6082	5.9	36

66	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?. <i>Biological Psychiatry</i> , 2017 , 82, 858-860	7.9	9
65	Prazosin during threat discrimination boosts memory of the safe stimulus. <i>Learning and Memory</i> , 2017 , 24, 597-601	2.8	10
64	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , 2017 , 42, 1210-1219	8.7	179
63	Ketamine for Depression: An Update. <i>Biological Psychiatry</i> , 2016 , 80, 416-418	7.9	14
62	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. <i>Nature Communications</i> , 2016 , 7, 11671	17.4	74
61	Cortical abnormalities and association with symptom dimensions across the depressive spectrum. <i>Journal of Affective Disorders</i> , 2016 , 190, 529-536	6.6	27
60	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , 2016 , 37, 3214-23	5.9	87
59	Ketamine for treatment-resistant depression: recent developments and clinical applications. <i>Evidence-Based Mental Health</i> , 2016 , 19, 35-8	11.1	73
58	Ketamine Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies 2016 , 99-121		1
57	Depressive Disorders 2016 , 57-73		
56	Functional Neuroanatomy 2016 , 12-17		
55	Clinical Use of Laboratory Tests, Brain Imaging, and Biomarkers 2016 , 28-39		
54	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016 , 173, 816-26	11.9	276
53	Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. <i>Psychopharmacology</i> , 2015 , 232, 1497-9	4.7	1
52	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2015 , 5, e509	8.6	65
51	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. <i>Psychological Medicine</i> , 2015 , 45, 3571-80	6.9	181
50	Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2015 , 40, 1084-90	8.7	89
49	Ketamine for posttraumatic stress disorder--reply. <i>JAMA Psychiatry</i> , 2015 , 72, 95-6	14.5	4

48	Emerging drugs for the treatment of anxiety. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 393-406	3.7	73
47	"Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?". <i>Current Treatment Options in Psychiatry</i> , 2015 , 2, 383-393	3.1	2
46	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015 , 2, 216-225	1.7	11
45	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015 , 1345, 47-58	6.5	56
44	Ketamine safety and tolerability in clinical trials for treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 247-52	4.6	136
43	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 16136-41	11.5	424
42	Current Treatments for Anxiety and Obsessive-Compulsive Disorders. <i>Current Treatment Options in Psychiatry</i> , 2014 , 1, 248-262	3.1	1
41	In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. <i>Neuroscience Letters</i> , 2014 , 569, 74-9	3.3	35
40	A randomized controlled trial of intranasal ketamine in major depressive disorder. <i>Biological Psychiatry</i> , 2014 , 76, 970-6	7.9	277
39	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 331-6	5.8	149
38	Cerebellar morphology and the effects of stimulant medications in youths with attention deficit-hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2014 , 39, 718-26	8.7	45
37	Advances in Psychopharmacology for Anxiety Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2014 , 12, 152-162	1.1	8
36	Cognitive-emotional training as an intervention for major depressive disorder. <i>Depression and Anxiety</i> , 2014 , 31, 699-706	8.4	41
35	Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. <i>Depression and Anxiety</i> , 2014 , 31, 335-43	8.4	220
34	Attention bias variability and symptoms of posttraumatic stress disorder. <i>Journal of Traumatic Stress</i> , 2014 , 27, 232-239	3.8	113
33	Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. <i>JAMA Psychiatry</i> , 2014 , 71, 681-8	14.5	337
32	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biological Psychiatry</i> , 2013 , 74, 250-6	7.9	498
31	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2013 , 231, 481	4.7	57

30	Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. <i>American Journal of Psychiatry</i> , 2013 , 170, 1134-42	11.9	725
29	Novel glutamatergic drugs for the treatment of mood disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 1101-12	3.1	68
28	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. <i>NMR in Biomedicine</i> , 2012 , 25, 1073-87	4.4	106
27	Ketamine for treatment-resistant unipolar depression: current evidence. <i>CNS Drugs</i> , 2012 , 26, 189-204	6.7	170
26	Is there anything really novel on the antidepressant horizon?. <i>Current Psychiatry Reports</i> , 2012 , 14, 643-9	1	52
25	Neurobiology of resilience. <i>Nature Neuroscience</i> , 2012 , 15, 1475-84	25.5	715
24	Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2012 , 36, 2104-9	3.7	38
23	CHAPTER 9: Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder. <i>RSC Drug Discovery Series</i> , 2012 , 226-257	0.6	
22	Ketamine as a novel antidepressant: from synapse to behavior. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 303-9	6.1	129
21	ECT in treatment-resistant depression. <i>American Journal of Psychiatry</i> , 2012 , 169, 1238-44	11.9	154
20	The serotonin transporter and emotionality: risk, resilience, and new therapeutic opportunities. <i>Biological Psychiatry</i> , 2011 , 69, 510-2	7.9	19
19	Reply to: Dose- and Exposure-Response to Ketamine in Depression. <i>Biological Psychiatry</i> , 2011 , 70, e11-e13	1.3	6
18	The serotonin 1B receptor: a new target for depression therapeutics?. <i>Biological Psychiatry</i> , 2011 , 69, 714-5	7.9	13
17	Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. <i>Biological Psychiatry</i> , 2011 , 70, 1033-8	7.9	66
16	Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , 2011 , 96, 553-63	3.1	222
15	A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>European Neuropsychopharmacology</i> , 2011 , 21, 221-9	1.2	38
14	Reduced ventral striatal/ventral pallidal serotonin 1B receptor binding potential in major depressive disorder. <i>Psychopharmacology</i> , 2011 , 213, 547-53	4.7	96
13	The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. <i>Archives of General Psychiatry</i> , 2011 , 68, 892-900		61

12	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. <i>Psychiatric Annals</i> , 2011 , 41, 408-412	0.5	3
11	A case of sustained remission following an acute course of ketamine in treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 414-5	4.6	31
10	Cracking the moody brain: lifting the mood with ketamine. <i>Nature Medicine</i> , 2010 , 16, 1384-5	50.5	26
9	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 71-82	5.8	197
8	Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. <i>Biological Psychiatry</i> , 2010 , 67, 139-45	7.9	480
7	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. <i>Modern Problems of Pharmacopsychiatry</i> , 2010 , 89-100		1
6	Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. <i>NMR in Biomedicine</i> , 2010 , 23, 643-50	4.4	57
5	Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. <i>Biological Psychiatry</i> , 2009 , 65, 792-800	7.9	177
4	A functional magnetic resonance imaging study of deliberate emotion regulation in resilience and posttraumatic stress disorder. <i>Biological Psychiatry</i> , 2009 , 66, 656-64	7.9	178
3	Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. <i>American Journal of Psychiatry</i> , 2006 , 163, 1784-90	11.9	374
2	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. <i>Brain Research</i> , 2000 , 883, 125-30	3.7	8
1	Ultra-high field MRI reveals mood-related circuit disturbances in depression: A comparison between 3-Tesla and 7-Tesla		1